AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?

 
• By Andrew McConaghie

Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.

AZ courtyard
The company is finalizing its long-term strategy, with more details expected at an investor day in May at its R&D headquarters in Cambridge, UK.

More from Earnings

More from Business